"$CNTA Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) https://t.co/9GYEZNjHXv"

Lixar (lixivaptan) - Centessa

Jun 2, 2022